Unknown

Dataset Information

0

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.


ABSTRACT: In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.

SUBMITTER: Luetkemeyer AF 

PROVIDER: S-EPMC4542662 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Luetkemeyer Anne F AF   Rosenkranz Susan L SL   Lu Darlene D   Grinsztejn Beatriz B   Sanchez Jorge J   Ssemmanda Michael M   Sanne Ian I   McIlleron Helen H   Havlir Diane V DV   Haas David W DW  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20150226 12


In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations. ...[more]

Similar Datasets

| S-EPMC3879806 | biostudies-literature
| S-EPMC6170200 | biostudies-literature
| S-EPMC9188543 | biostudies-literature
| S-EPMC8653639 | biostudies-literature
| S-EPMC5623109 | biostudies-literature
| S-EPMC3719885 | biostudies-literature
| S-EPMC2679896 | biostudies-literature
| S-EPMC6325194 | biostudies-literature
| S-EPMC4135849 | biostudies-literature
| S-EPMC4892230 | biostudies-literature